Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 15/20 | 0.55 |
| ▸ | CDK2 | P24941 | 9/20 | 0.55 |
| ▸ | CCND3 | P30281 | 9/20 | 0.53 |
| ▸ | CDK1 | P06493 | 7/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | CDK7 | P50613 | 3/20 | 0.52 |
| ▸ | CDK9 | P50750 | 3/20 | 0.52 |
| ▸ | CCND1 | P24385 | 8/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | STK16 | O75716 | 1/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2514899 | 1.00 | CDK4 (0.55) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19836706 | 0.92 | CDK4 (0.54) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19836272 | 0.92 | CDK4 (0.51) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL20987197 | 0.90 | EGFR (0.46) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL20987199 | 0.88 | CDK4 (0.53) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL22172140 | 0.88 | EGFR (0.46) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL21522745 | 0.88 | CDK4 (0.54) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL30309496 | 0.88 | EGFR (0.46) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL30888974 | 0.88 | CDK4 (0.54) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL30309451 | 0.88 | CDK4 (0.53) | CDK4CDK6CDK2CCND3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063436-A | Preparation method of arbeli | 山东铂源药业股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| EP-4626423-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025080753-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-117510471-B | Abeli synthesis method | 江苏天士力帝益药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-114901666-B | Selective CDK4/6 inhibitor type cancer therapeutic drug | 卢内拉生物技术有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119285639-A | CDK9 protein degradation targeting chimeras | 斯迈旭(北京)生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024256569-A1 | NOVEL CDK DEGRADERS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2024-12-19 | — | — | WO | disclosed |
| CN-118652252-A | Selective CDK4/6 inhibitor type cancer therapeutic drug | 卢内拉生物技术有限公司 | 2024-09-17 | — | — | CN | disclosed |
| EP-3398947-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-117510471-A | Abeli synthesis method | 江苏天士力帝益药业有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2023205892-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023177451-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | EnhancedBio Inc. (KR) | 2023-09-21 | — | — | WO | disclosed |
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-4077325-A1 | SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS | Lunella Biotech, Inc. (CA) | 2022-10-26 | — | — | EP | disclosed |
| CN-115057845-A | Preparation method of Abelide | 山东罗欣药业集团恒欣药业有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-115023424-A | Selective CDK4/6 inhibitor type cancer therapeutic drug | 卢内拉生物技术有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-114901666-A | Selective CDK4/6 inhibitor type cancer therapeutic drug | 卢内拉生物技术有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114605390-A | Compound with CDK kinase inhibitory activity, pharmaceutical composition and use thereof | 上海凌达生物医药有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-109071552-B | Degradation of cyclin dependent kinase 4/6(CDK4/6) by conjugation of CDK4/6 inhibitors to E3 ligase ligands and methods of use | 达纳－法伯癌症研究所公司 | 2022-06-03 | — | — | CN | disclosed |